Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Income from Continuing Operations (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Income from Continuing Operations for 8 consecutive years, with 13483952.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 37.59% to 13483952.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 70090704.0, a 39.7% decrease, with the full-year FY2025 number at 63979492.0, up 15.11% from a year prior.
  • Income from Continuing Operations was 13483952.0 for Q4 2025 at Outlook Therapeutics, up from 14847398.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 13483952.0 in Q4 2025 to a low of 21606852.0 in Q4 2024.